Trestle Biotherapeutics

Trestle Biotherapeutics is an ambitious, early-stage biotech focused on transforming the treatment of kidney failure through tissue engineering. The company is developing an implantable bioengineered tissue designed to restore kidney function, addressing a massive unmet need for the over 850,000 patients worldwide dependent on dialysis. Led by a seasoned team with deep expertise in 3D bioprinting and stem cell biology from Organovo, Trestle is building a platform that could eventually be applied to other organ systems. The company is currently in the preclinical development phase and is backed by undisclosed advisors and investors.

Platform integrating stem cell biology, 3D biofabrication, and fluidics to create implantable, functional therapeutic tissues.

Competition includes companies developing xenotransplantation (e.g., eGenesis), wearable artificial kidneys (e.g., AWAK, Wearable Artificial Organs), and cell therapies. Large dialysis providers (Fresenius, DaVita) represent incumbent service models but are also potential partners or acquirers for a disruptive technology. Trestle's tissue engineering approach is among the most ambitious and technically challenging.